<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064830</url>
  </required_header>
  <id_info>
    <org_study_id>09-1141</org_study_id>
    <nct_id>NCT01064830</nct_id>
  </id_info>
  <brief_title>Topical Cyclosporine Suspension for the Treatment of Brittle Nails</brief_title>
  <official_title>A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brittle nail syndrome (BNS) refers to nails that exhibit splitting, raggedness (fraying of
      the distal edge), and peeling (lamellar onychoschizia).(1) This is a common problem,
      affecting approximately 20% of women, with higher prevalence among the elderly.(2) A number
      of factors have been proposed as possible causes of nail brittleness, such as anemia, biotin
      deficiency, or cysteine deficiency. (3,4) However, most authors believe that brittle nails
      are usually caused by dehydration of the nail plate, either from repetitive cycles of
      hydration and dehydration related to hand washing or from exposure to dehydrating chemicals,
      such as those found in nail enamel and cuticle removers. (5,6) Inflammation of the nail as a
      potential contributing factor has never been studied.

      There are currently not consistently effective treatments for this condition. Restasis® is
      effective in treating keratoconjunctivitis sicca. This condition is characterized by the
      troublesome condition of dry eyes partially due to decreased tear production exacerbated by
      inflammation. The BNS manifests itself by nail plate dehydration. The two conditions have in
      common disruption of water balance which gives rise to problematic clinical disorders. The
      hypothesis is that a product which benefits tear production would also be effective for
      brittle nails which contain roughly 15% water.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brittle nail syndrome (BNS) is a heterogeneous abnormality, characterized by increased
      fragility of the nail plate. About 20% of the population is affected by brittle nails and
      women are affected twice as frequently as men. (2). The diagnostic criteria for brittle nails
      are not well defined but most authors agree in at least these 3 criteria: onychoschizia
      (lamellar splitting of the free edge and distal portion of the nail plate), onychorrhexis
      (longitudinal thickening and thinning or ridging of the nail plate) and fraying or raggedness
      of the distal edge causing transverse splitting.

      Although the cause of nail brittleness is unknown, most authors believe that it is caused by
      dehydration of the nail plate and that frequent cycles of hydration and dehydration as well
      as various mechanical and chemical insults increase the incidence of brittle nails. (7) The
      nail plate contains about 15% water and a very low lipid content so water permeation through
      the nail plate is high.(8) In fact, it has been demonstrated that the flux of water across
      the nail plate is 10 times more than the epidermis and 1000 times more permeable than the
      stratum corneum.(9) A recent report show that there was no significant difference in water
      content of brittle nails when compared to normal nails and suggested that nail plate water
      content is random and that nail plates are in a constant state of influx and efflux of water.
      (10) Keratoconjunctivitis sicca is a chronic, bilateral desiccation of the conjunctiva and
      cornea due to an inadequate tear film. There are two types: one caused by an inadequate tear
      volume and the other one caused by an accelerated tear evaporation due to poor tear quality
      (11). Restasis® (cyclosporine 0.05% topical emulsion) is effective in treating
      keratoconjunctivitis sicca.

      BNS and keratoconjunctivitis sicca have in common a disruption of water balance which gives
      rise to problematic clinical disorders. We hypothesize that a product which improves corneal
      dehydration would also be effective for brittle nails. Our rationale for using occlusion is
      that is has been shown that occluding the skin with a vapor-permeable membrane increases the
      water flux and the barrier function is recovered at a normal rate. (12) We also hypothesize
      that using Restasis® (cyclosporine 0.05% topical emulsion) or its vehicle (Refresh Dry Eye
      Therapy®) under occlusion with a finger cot will increase the nail plate hydration balance
      and as a consequence will improve nail brittleness. Topical cyclosporine has been shown to be
      safe in the treatment of other dermatological conditions such as nail psoriasis and oral
      lichen planus. (13,14) An investigator-blinded design will differentiate if the observed
      effects are caused by the active ingredient in Restasis® (cyclosporine 0.05% topical
      emulsion) or its vehicle (Refresh Dry Eye Therapy®).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails.</measure>
    <time_frame>20 weeks</time_frame>
    <description>IN a scale of 0-3 where 0 means normal nail and 3 means severe disease, the number of patients who received at least a decrease of 1 grade in the evaluation of two target nails</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Assessment of Satisfaction With Length of Fingernails</measure>
    <time_frame>20 weeks</time_frame>
    <description>the percentages of participants who were satisfied with the &quot;length of fingernails&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Brittle Nail Syndrome</condition>
  <arm_group>
    <arm_group_label>topical cyclosporine suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apply 2 drops to 2 target nails under occlusion daily for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>apply to target nails daily under occlusion daily for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topical cyclosporine ophthalmic suspension 0.05%</intervention_name>
    <description>apply 2 drops to 2 target fingernails under occlusion daily</description>
    <arm_group_label>topical cyclosporine suspension</arm_group_label>
    <other_name>Restasis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle</intervention_name>
    <description>apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks</description>
    <arm_group_label>vehicle</arm_group_label>
    <other_name>Refresh Dry Eye Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Must understand and voluntarily sign an informed consent form

               -  Must be male or female and aged 18-75 years at time of consent

               -  Must be able to adhere to the study visit schedule and other protocol
                  requirements

               -  At least 2 of the following: raggedness (fraying of the distal edge), splitting,
                  and peeling (lamellar onychoschizia) of 2 target fingernails of the same hand. If
                  the subject does not have 2 fingernails affected in the same hand, a second
                  fingernail on the other hand may be used as control.

               -  A direct microscopic examination with potassium hydroxide (KOH)/calcofluor that
                  is negative for hyphae associated with dermatophytes

               -  Women of childbearing potential must have a negative pregnancy test at enrollment

        Exclusion Criteria:

          -  Inability to provide voluntary consent

          -  Pregnant or breastfeeding

          -  Fingernail fungal infection

          -  Use of any investigational medication within 4 weeks prior to start of study drug

          -  Subject has any known immunodeficiency or history of malignancy in the last 4 years,
             excluding nonmelanoma skin cancer.

          -  Use of any topical nail medication for 2 weeks

          -  Use of any topical nail product (nail polish, hardeners, acetone, etc) for 1 week
             prior to and during the study.

          -  Use of biotin 2 weeks before enrollment.

          -  No genetic nail abnormalities

          -  Known sensitivity to Restasis® or RDET®.

          -  Subject has psoriasis, lichen planus, or other abnormalities that could result in a
             clinically abnormal fingernail
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aida Lugo-Somolinos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC- Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <results_first_submitted>October 2, 2012</results_first_submitted>
  <results_first_submitted_qc>November 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2012</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Aida Lugo-Somolinos, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>brittle nail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyclosporine Solution 0.05% (Restasis®)</title>
          <description>Topical Cyclosporine 0.05% Ophthalmic Suspension</description>
        </group>
        <group group_id="P2">
          <title>Vehicle (Refresh Dry Eye Therapy®)</title>
          <description>Topical vehicle: Refresh Dry Eye Therapy® (ophthalmic solution of glycerin 1% and polysorbate 80 1%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclosporine Solution</title>
          <description>apply to affected nails at night</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>apply to affected nails at night</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="17.76"/>
                    <measurement group_id="B2" value="54.8" spread="10.02"/>
                    <measurement group_id="B3" value="51.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>• Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails.</title>
        <description>IN a scale of 0-3 where 0 means normal nail and 3 means severe disease, the number of patients who received at least a decrease of 1 grade in the evaluation of two target nails</description>
        <time_frame>20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Solution</title>
            <description>topical</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>topical</description>
          </group>
        </group_list>
        <measure>
          <title>• Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails.</title>
          <description>IN a scale of 0-3 where 0 means normal nail and 3 means severe disease, the number of patients who received at least a decrease of 1 grade in the evaluation of two target nails</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Assessment of Satisfaction With Length of Fingernails</title>
        <description>the percentages of participants who were satisfied with the &quot;length of fingernails&quot;</description>
        <time_frame>20 weeks</time_frame>
        <population>all patients enrolled who completed this response measure at week 20.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Solution</title>
            <description>cyclosporine solution</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Assessment of Satisfaction With Length of Fingernails</title>
          <description>the percentages of participants who were satisfied with the &quot;length of fingernails&quot;</description>
          <population>all patients enrolled who completed this response measure at week 20.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cyclosporine Solution</title>
          <description>topical</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>topical</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Virus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>herpes labialis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>inner ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>strept throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ductal breast cancer (Stage 1 )</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>surgery for breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>poison ivy contact dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aida Lugo-Somolinos MD</name_or_title>
      <organization>University of North carolina-Chapel Hill</organization>
      <phone>919-843-9447</phone>
      <email>alugosom@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

